BridgeBio Oncology Therapeutics, Inc.
For the period ended Sep 30, 2026. Filed Nov 10, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Operations
(In thousands, except share and per share data)
| Three Months Ended September 30, | Nine Months Ended September 30, | |||
|---|---|---|---|---|
| 2026 | 2025 | 2026 | 2025 | |
| Operating expenses: | ||||
| Research and development(1) | $29,593 | $35,052 | $118,620 | $83,125 |
| General and administrative(2) | 7,895 | 14,129 | 25,234 | 19,286 |
| Total operating expenses | 37,488 | 49,181 | 143,854 | 102,411 |
| Loss from operations | (37,488) | (49,181) | (143,854) | (102,411) |
| Other income, net: | ||||
| Interest income | 3,262 | 3,444 | 10,757 | 6,919 |
| Income from transition services agreements | 87 | 1,010 | 506 | 1,010 |
| Change in fair value of participation right liability | — | — | — | (725) |
| Other expense | (37) | (30) | (145) | (40) |
| Total other income, net | 3,312 | 4,424 | 11,118 | 7,164 |
| Net loss | $(34,176) | $(44,757) | $(132,736) | $(95,247) |
| Net loss per share attributable to common stockholders, basic and diluted | $(0.43) | $(1.03) | $(1.66) | $(6.49) |
| Weighted-average number of shares used in computing net loss per share attributable to common stockholders, basic and diluted | 80,184,540 | 43,491,085 | 80,110,047 | 14,684,990 |
(1)
Research and development expe nses include related party amounts of $3 and $153 for thethree months ended September 30, 2026 and 2025, respectively, and $376 and $590 for thenine months ended September 30, 2026 and 2025, respectively.
(2)
General and administrative expenses include related party amounts of $7 and $7,905 for thethree months ended September 30, 2026 and 2025, respectively, and $85 and $8,274 for thenine months ended September 30, 2026 and 2025, respectively.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.